Filtered By: Scitech

Regeneron antibodies help asymptomatic and hospitalized patients; Some lymph node cancers limit vaccine response

The following is a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus.

Regeneron COVID-19 drug helps hardly sick and hospitalized patients

An antibody cocktail from Regeneron Pharmaceuticals Inc and Roche showed benefits for a wide range of COVID-19 patients, from those without symptoms to hospitalized patients whose immune systems have not mounted a natural antibody response to the virus, two research teams reported on medRxiv ahead of peer review.

The cocktail, REGEN-COV, is already being used intravenously in the United States to keep symptomatic COVID-19 patients out of the hospital.

In a large new trial in US adults and adolescents with coronavirus detected in the nose but no symptoms, researchers compared the effects of a single under-the-skin injection of the drug to a placebo.

The results, released on Monday, showed the treatment cut patients' risk of developing symptoms by 32%.

It also reduced the amount of virus patients carry, said study leader Meagan O'Brien of Regeneron.

When symptoms did develop, they resolved five-to-six days faster with the drug.

No one who got the drug required an emergency room visit or hospitalization, compared to six people in the placebo group.

In a separate study from the UK released on Wednesday, intravenous treatment with REGEN-COV reduced the risk of death in hospitalized patients whose immune systems had not produced antibodies to the coronavirus.

Treatment also shortened these patients' hospital stays and reduced their odds of needing mechanical ventilation.

No benefit was seen, however, in patients who already had their own antibodies.

Some lymph node cancers limit COVID-19 vaccine responses

Some patients with lymph node cancers will have good antibody responses to COVID-19 vaccines, but others will need further protection, according to new data.

The UK PROSECO study tested antibody levels in 129 lymphoma patients after their first and/or second dose of the Pfizer/BioNTech or AstraZeneca vaccines.

Responses were mixed, researchers reported on Saturday on medRxiv ahead of peer review.

Patients vaccinated during or within six months after treatment for their blood cancer were unlikely to develop good antibody responses, researchers found.

These patients need to be revaccinated, said study leader Dr. Sean Hua Lim of the University of Southampton.

Among patients who had never received treatment, or who had completed treatment more than six months prior, those with curable lymphomas responded well to the vaccine.

All five with Hodgkin lymphoma, and seven of eight with aggressive B-cell lymphomas developed strong antibody responses.

But 18 of 36 patients with incurable indolent lymphomas, like follicular lymphoma, had lower antibody levels than other patient groups.

For these patients, "further measures such as boosting with a different vaccine, or prophylactic treatment with antibodies should be considered," Lim said. -- Reuters